Illumina launches new software to enable tertiary analysis for oncology applications, and soon rare diseasePRNewsWire • 03/27/23
Carl Icahn claims Illumina directors got extra insurance to close 'disastrous' $7.1 billion Grail dealCNBC • 03/24/23
Illumina shares attractive as conclusion to Grail saga draws closer, broker saysProactive Investors • 03/20/23
Biotech company Illumina pushes back against Carl Icahn's proxy fight over $7.1 billion Grail dealCNBC • 03/20/23
Illumina Underscores Commitment to Shareholder Value and Responds to Carl Icahn's StatementsPRNewsWire • 03/20/23
Icahn proposes three candidates for Illumina's board — Here's what could be next in the battleCNBC • 03/18/23
Illumina retains ‘Buy' rating from Canaccord as activist investor Carl Icahn prepares for face-offProactive Investors • 03/14/23
Illumina launches its first product enabling long- and short-read sequencing on one instrumentPRNewsWire • 03/14/23
Illumina: It's not in the ‘best interests' of shareholders to support Carl Icahn's nominees to the boardMarket Watch • 03/13/23
'Something is rotten in the state of Illumina,' says activist investor Carl Icahn as he takes aim over Grail pursuitProactive Investors • 03/13/23
Illumina Surges As Activist Carl Icahn Reportedly Steps In Over GrailInvestors Business Daily • 03/13/23
ILMN Stock Alert: What to Know as Carl Icahn Prepares for Proxy Fight With IlluminaInvestorPlace • 03/13/23